A comparable 32% decrease in plasma CHOL levels were also observed in HFD-fed Dysf-null mice treated with ezetimibe compared to vehicle controls in absence of profound atherosclerosis, further confirming that dysferlin does not effect intestinal cholesterol blockade, despite robust enterocyte expression (Figure 4C). This evidence concerns the gene DYSF and atherosclerosis.